Immune thrombocytopenia is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x10⁹/L with no known cause (Rodeghiero et al, 2009). The incidence is estimated to be 1.6 to 3.9 per 100,000 patient-years in adults and 0.46 to 12.5 per 100,000 patient-years in children (Terrell et al, 2010). Research has shown that the burden of ITP is significant. A survey of more than 1,300 patients across 13 countries showed 36% reported a high impact on emotional well-being and 28% on ability to work (Cooper et al, 2018). Furthermore, nearly two-thirds reported fatigue as the most severe symptom, underscoring the effect of ITP on day-to-day quality of life. Current gaps in knowledge, including the lack of specific diagnostic criteria and uncertainty about the true frequency of bleeding events, limit effective management (Neunert et al, 2015). In addition, the dearth of prospective trials evaluating new treatment options represents an important unmet need.